A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

Study identifier:D9090C00003

ClinicalTrials.gov identifier:NCT05395117

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A fixed sequence, open-label study to assess the effect of multiple doses of AZD5462 on the pharmacokinetics of oral midazolam (CYP3A4 probe), rosuvastatin (OATP1B1/3, BCRP probe), and digoxin (P-gp probe) in healthy participants

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5462, Midazolam, Rosuvastatin, Digoxin

Sex

All

Actual Enrollment

32

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 30 Jun 2022
Primary Completion Date: 12 Sept 2022
Study Completion Date: 12 Sept 2022

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria